Short answer
Voyager Therapeutics, Inc. (VYGR) filed an 8-K current report with the SEC on March 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year 2025 earnings released March 9, 2026 via press release (Exhibit 99.1).
Voyager Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 earnings released March 9, 2026 via press release (Exhibit 99.1)
- Full financial details in Exhibit 99.1: primary source for revenue, cash position, and pipeline spending
- Filing signed by CEO Alfred Sandrock, M.D., Ph.D., confirming executive authorization
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Voyager Therapeutics, Inc. 8-K filings
Get the next VYGR 8-K as it lands
Follow VYGR for push alerts, or ask the research agent what this filing means.